Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DCIX20
|
|||
| Drug Name |
ADU- S100
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Head and neck cancer [ICD-11: 2D42; ICD-9: 199] | Phase 2 | [1] | |
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Stimulator of interferon genes protein (TMEM173) | Target Info | Agonist | [2] |
| KEGG Pathway | NOD-like receptor signaling pathway | |||
| RIG-I-like receptor signaling pathway | ||||
| Cytosolic DNA-sensing pathway | ||||
| Human cytomegalovirus infection | ||||
| Herpes simplex virus 1 infection | ||||
| Human immunodeficiency virus 1 infection | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03937141) Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Magnitude of Therapeutic STING Activation Determines CD8 + T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.